31 augustus 2017: Lees ook dit artikel:
11 december 2012: over onderstaand bericht staat vandaag 11 december 2012 een groot artikel: Leukemie: Omgebouwd hiv-virus wapen tegen kanker
16 juli 2012: Bron CBS news
Een bepaalde vorm van immuuntherapie - gentherapie bij 3 patiënten met leukemie zorgt voor succes. Zo succesvol dat CBS news daarover een reportage maakte Is dit succes toeval of een bewijs dat deze aanpak ook werkt? In deze aanpak werden er via aftappen van eigen bloedcellen buiten de patiënt om nieuwe T-cellen aangemaakt en deze werden via zogeheten beads - bolletjes die inwendig de inhoud gedoseerd loslaten opnieuw bij de patiënt ingebracht. Ter attentie in september 2012 wordt in het Anthonie van Leeuwenhoek - AvL met een soortgelijke aanpak gestart met melanoompatiënten al worden de gekweekte T-cellen dan via de lymfklieren teruggebracht. Zie dit artikel Soms kan het eigen lichaam meer dan gedacht - kanker overwinnen, bijvoorbeeld. Mits het een beetje wordt geholpen. onder melanoom informatie.
Hier de begeleidende tekst naast de CBS beelden:
New leukemia therapy destroys cancer by turning blood cells into "assassins"
(CBS/AP) A new leukemia treatment has experts buzzing over a possible cure that may one day change cancer treatment forever.
How does it work? According to experts, the treatment is a gene therapy that turns a patient's own blood cells into assassins that tracks down and destroys cancer cells.
They've only tested it in three patients so far, but the results were noteworthy. Two patients appear cancer-free a year after treatment, and the third patient still has some cancer but is improved.
"It worked great," said study author Dr. Carl June, professor of pathology and laboratory medicine at the University of Pennsylvania. "We were surprised it worked as well as it did."
Currently, the only hope for a cure is bone marrow or stem cell transplants, which don't always work and can be fatal.
Scientists have been trying for years to find ways to boost the immune system's cancer-fighting ability. Earlier attempts at genetically modifying T-cells, our "bloodstream soldiers," have had limited success -the modified cells didn't reproduce well and quickly vanished.
June and his colleagues used a new technique to deliver the new genes into the T-cells with a signal that tells the cells to kill and multiply. That resulted in armies of "serial killer" cells that targeted and destroyed cancer cells, even new cancer cells as they emerged. T-cells typically attack viruses that way, but June says this is the first time it's been done against cancer.
For the study - published in the "New England Journal of Medicine" and "Science Translational Medicine" - scientists took blood from three patients with very advanced cases of chronic lymphocytic leukemia and genetically altered it in a lab. Then the scientists returned the blood cells to the patients in three infusions.
The scientists detailed the experience of one 64-year-old patient. There was no change for two weeks, but then he became ill with fever, nausea, and chills. He and the other two patients were hit with this condition that occurs when a lot of cancer cells die at the same time - a sign that the gene therapy is working.
"It was like the worse flu of their life," June said. "But after that, it's over - they're well."
The main complication from the therapy seems to be that it also destroys some other infection-fighting blood cells, requiring additional monthly treatments for the patients.
Scientists now want to test the gene therapy technique in leukemia-related cancers, as well as pancreatic and ovarian cancer, June said. Other institutions are looking at prostate and brain cancer.
"This is a form of what I would call ultimate personal therapy," June told CBS News' Dr. Jon LaPook. That's a wave of the future."
Dr. Walter J. Urba, director of cancer research at the Providence Cancer Center in Portland, Ore., called the findings "pretty remarkable" but was cautiously optimistic because of the study's size.
"It's still just three patients," said Urba, one of the authors of an accompanying editorial in the New England Journal. Three's better than one, but it's not 100." He says the key is what happens to these patients years from now.
Dr. Kanti Rai, chief of hematology, oncology at North Shore-Long Island Jewish Medical Center in N.Y., could hardly contain his enthusiasm despite being admittedly more reserved when he comments on studies like these.
"It's an amazing, amazing kind of achievement," he said.
One of the patients released a statement through the university. The man who did not want to be identified, himself a scientist, said he's "very lucky."
Although he wrote that he didn't feel that way when he was first diagnosed 15 years ago at age 50. He was treated successfully with chemotherapy for years until standard drugs no longer worked.
How is he now?
"I'm healthy and still in remission," the man said. "I know this may not be a permanent condition, but I decided to declare victory and assume that I had won."
More than 44,000 Americans are diagnosed with leukemia each year while nearly 22,000 succumb to the disease.
The National Cancer Institute has more on leukemia.
Gerelateerde artikelen
- Anti CD-19 CAR T-celtherapie gegeven aan patienten met gevorderde B-cel Acute Lymfatische Leukemie met uitzaaiingen in beenmerg en het centrale zenuwstelsel geeft hele goede resultaten
- Met WT1 mRNA versterkte dendritische cellen voorkomen recidief bij 43% van de patiënten met AML - Acute Myeloide Leukemie die in remissie kwamen na chemotherapie.
- Anti-CD19 CAR T-celtherapie geeft langdurige ziektevrije tijd en duurzame complete remissies bij patiënten met Chronische Lymfatische Leukemie (CLL).
- Nieuwe biomarkers (mutaties CD27-pos, CD45RO-neg.en CD8+) CAR T cellen voorspellen waarom immuuntherapie met T-car cells bij CLL - Chronische Lymfatische Leukemie effectief zal zijn.
- Immuuntherapie en gerichte therapie: Lymfklierkanker en leukemie kennen verschillende vormen en stadia. Hier een recente studie van de belangrijkste behandelingsopties, vooral met vormen van immuuntherapie copy 1
- Immuuntherapie met CAR T-Cell Therapy (tisagenlecleucel (Kymriah) goedgekeurd door FDA voor gebruik bij kinderen en jong volwassenen met vorm van Acute Lymfatische Leukemie (ALL).
- Twee kinderen met ongeneeslijke vorm van ALL - Acute Lymfatische Leukemie blijken alsnog te genezen door immuuntherapie met T-cellen van een donor via T-cell enginering therapie.
- Immuuntherapie met gemanipuleerde T-cellen geeft spectaculair goede resultaten bij patienten met vergevorderde leukemie en B-cel lymfomen copy 1
- Gen therapie bij leukemie blijkt succesvol bij enkele patienten. Toeval of doorbraak in immuuntherapie?
- Immuuntherapie: Vaccin geeft hoop in kleinschalige studie tegen CML na resistentie voor Gleevec.
- Immuuntherapie: Vaccin ontwikkelt tegen leukemie in LUMC - Leids Universitair Medisch Centrum
- Immuuntherapie: Actuele stand van zaken van immunotherapie met Mabthera/Rituxan/rituxemab bij o.a. CLL - Chronische Lymfatische Leukemie. Een aantal artikelen bij elkaar gezet.
- Immuuntherapie: Gentherapie afdeling in UMC gaat trial doen met leukemie en extra ingebrachte T-cellen met zelfmoordcommando gen
Plaats een reactie ...
Reageer op "Gen therapie bij leukemie blijkt succesvol bij enkele patienten. Toeval of doorbraak in immuuntherapie?"